Roivant Sciences Ltd (ROIV)
11.04
+0.16
(+1.42%)
USD |
NASDAQ |
Apr 26, 16:00
11.04
0.00 (0.00%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 8.893B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 24.49% |
| Valuation | |
| PE Ratio | 2.122 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 69.75 |
| Price to Book Value | 1.460 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.0737 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | -- |
Profile
| Roivant Sciences Ltd is a biopharmaceutical company dedicated to improving the delivery of healthcare to patients. |
| URL | https://www.roivant.com |
| Investor Relations URL | https://investor.roivant.com/ |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Mid Cap/Blend |
| Next Earnings Release | Jun. 28, 2024 (est.) |
| Last Earnings Release | Feb. 13, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Roivant Sciences Ltd is a biopharmaceutical company dedicated to improving the delivery of healthcare to patients. |
| URL | https://www.roivant.com |
| Investor Relations URL | https://investor.roivant.com/ |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Mid Cap/Blend |
| Next Earnings Release | Jun. 28, 2024 (est.) |
| Last Earnings Release | Feb. 13, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |